Compare AbCellera Biologics Inc (ABCL) vs 3M Company (MMM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs 3M Company — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while 3M Company trades at $154.93 (market cap $82.41B). The key difference: 3M Company is far larger — about 35.1× AbCellera Biologics Inc's market cap, and 3M Company pays a 1.97% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MMM | |
|---|---|---|
Market Cap | $2.35B | $82.41B |
Sector | Health | Industrials |
52-Week High | $8.12 | $174.61 |
52-Week Low | $2.78 | $141.10 |
Enterprise Value | $1.99B | $90.82B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MMM trades at $158.00, down 1.52% today, with a bullish technical signal driven by moving averages. The company reported three consecutive quarterly EPS beats, with Q2 2026 results expected on July 21, 2026. Strong profitability metrics include a 72.14% ROE and 11.14% net margin, though revenue has declined from 2022 peaks. Recent news highlights partnerships with Airbus and an AI tool launch, supporting operational momentum.
Outlook is mixed: analyst consensus is a Hold with a $148.75 price target below current levels, citing limited AI exposure. Risks include volatile cash flows and high debt. Upside depends on execution of growth initiatives and margin improvement. The stock offers a dividend yield with the next payment on June 12, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
